Skip to main content
Article thumbnail
Location of Repository

Application release active antibodies in complex treatment of patients with benign prostatic hyperplasia

By B. U. Shalekenov and E. A. Kuandykov


<em><em></em></em><p align="LEFT">An assessment of the clinical effectiveness and safety without the danger of drugs Afala and Impaza in the complex treatment of patients with benign prostatic hyperplasia (BPH) and erectile dysfunction. The study involved 132 men aged 50 to 70 years. Depending on the treatment of BPH patients were divided into 4 groups: group 1 patients (n = 35) received only conservative therapy, patients in group 2 (n = 30) was performed photoselective laser vaporization (PLV) BPH. 3 groups of patients (n = 35) – transurethral resection (TUR) of BPH patients to 4 groups (n = 32) performed a combination of PLV and TUR BPH. Patients all groups received the drug Afala and Impaza. Following the comprehensive treatment of prostate volume reduction of 75 %, 90 % of patients showed an increase in urinary flow rate 15–17 ml/s, and improvement in QoL noted IPSS 89 %, normalization of sexual function – 78 % of patients.</p><em></em

Topics: benign prostatic hyperplasia, erectile dysfunction, ultra-small doses of antibodies, Afala, Impaza, Surgery, RD1-811, Diseases of the genitourinary system. Urology, RC870-923
Publisher: ABV-press
Year: 2013
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.